Can China Medical University Hospital, Ever Supreme and SHINE OUT BIO reshape spinal cord injury repair?
New exosome therapy targets spinal cord injury repair non-invasively. Find out how this breakthrough could reshape neuroregenerative medicine.
INTENT Biologics secures FDA pediatric waiver, clears path to late-stage DFU trial for PEP Biologic
The U.S. Food and Drug Administration (FDA) has granted INTENT Biologics a full pediatric study waiver for its lead candidate, PEP Biologic, under IND 019567. The waiver, part of an agreed Initial Pediatric Study Plan (iPSP), applies to the product’s adult-focused development for diabetic foot ulcers (DFUs), a serious chronic wound indication preparing for pivotal […]